StreetInsider.com News Articles

Form 8-K Quince Therapeutics, For: Aug 23

Thu, 27 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260827/26990491.html

Form 8-K Quince Therapeutics, For: Aug 23

Thu, 27 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260827/26990491.html

Form DEF 14A Quince Therapeutics, For: Oct 06

Tue, 25 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26971361.html

Form DEF 14A Quince Therapeutics, For: Oct 06

Tue, 25 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26971361.html

Form EFFECT Quince Therapeutics,

Tue, 25 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260825/26970329.html

Form EFFECT Quince Therapeutics,

Tue, 25 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260825/26970329.html

Craig-Hallum Starts Quince Therapeutics Inc. (QNCX) at Buy

Thu, 20 Aug 2026 07:16:38 -0400

Craig-Hallum analyst Albert Lowe initiates coverage on Quince Therapeutics Inc. (NASDAQ: QNCX) with a Buy rating and a price target of $68.00.

For an analyst ratings summary and ratings history on Quince Therapeutics Inc. click here. For more ratings news on Quince Therapeutics Inc. click here.

Shares of Quince Therapeutics Inc. closed at $34.57 yesterday.

Cantor Fitzgerald Reiterates Overweight Rating on Quince Therapeutics Inc. (QNCX)

Tue, 18 Aug 2026 09:00:49 -0400

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterated an Overweight rating and $70.00 price target on Quince Therapeutics Inc. (NASDAQ: QNCX).

The analyst commented, "We hosted Quince Therapeutics / Orphai management for a discussion around LAM-001, the company's once-daily inhaled formulation of rapamycin being developed across PH-ILD, bronchiolitis obliterans syndrome (BOS), and sarcoidosisassociated pulmonary hypertension (SAPH)...We came away incrementally more positive on the LAM-001 story after today’s discussion. The thesis here is relatively straightforward: take a well-understood drug and pathway, deliver it directly to the lung to maximize local activity (and limit systemic exposure), and develop it in pulmonary diseases where mTOR-driven

Form 8-K Quince Therapeutics, For: Aug 17

Mon, 17 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260817/26934310.html

Form 8-K Quince Therapeutics, For: Aug 17

Mon, 17 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260817/26934310.html

Form SCHEDULE 13G Quince Therapeutics, Filed by: Ikarian Capital, LLC

Fri, 14 Aug 2026 21:21:00 -0400

si-local-file:///var/storage/secattach/20260814/26933309.html

Form SCHEDULE 13G Quince Therapeutics, Filed by: Ikarian Capital, LLC

Fri, 14 Aug 2026 21:21:00 -0400

si-local-file:///var/storage/secattach/20260814/26933309.html

Form SCHEDULE 13G/A Quince Therapeutics, Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932173.html

Form SCHEDULE 13G/A Quince Therapeutics, Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932173.html

Form 10-Q Quince Therapeutics, For: Jun 30

Fri, 14 Aug 2026 16:11:00 -0400

http://archive.fast-edgar.com/20260814/A322A22FZZ2R82Z222JS2MYJVPSTEZ22N282

Filed on: August 14, 2026

Form 10-Q Quince Therapeutics, For: Jun 30

Fri, 14 Aug 2026 16:11:00 -0400

http://archive.fast-edgar.com/20260814/A322A22FZZ2R82Z222JS2MYJVPSTEZ22N282

Filed on: August 14, 2026

Form SCHEDULE 13G Quince Therapeutics, Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26928756.html

Form SCHEDULE 13G Quince Therapeutics, Filed by: Cormorant Asset Management, LP

Fri, 14 Aug 2026 14:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26928756.html

Form 8-K Quince Therapeutics, For: Aug 14

Fri, 14 Aug 2026 08:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26925025.html

Form 8-K Quince Therapeutics, For: Aug 14

Fri, 14 Aug 2026 08:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26925025.html

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline

LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027

Closed private placement financing, receiving $115 million in upfront gross proceeds, with potential for up to an additional $83 million upon exercise of warrants (including warrants issued to former Orphai stockholders)

Cash and cash equivalents of $116 million as of June 30, 2026, expected to

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline

LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027

Closed private placement financing, receiving $115 million in upfront gross proceeds, with potential for up to an additional $83 million upon exercise of warrants (including warrants issued to former Orphai stockholders)

Cash and cash equivalents of $116 million as of June 30, 2026, expected to

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline

LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027

Closed private placement financing, receiving $115 million in upfront gross proceeds, with potential for up to an additional $83 million upon exercise of warrants (including warrants issued to former Orphai stockholders)

Cash and cash equivalents of $116 million as of June 30, 2026, expected to

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline

LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027

Closed private placement financing, receiving $115 million in upfront gross proceeds, with potential for up to an additional $83 million upon exercise of warrants (including warrants issued to former Orphai stockholders)

Cash and cash equivalents of $116 million as of June 30, 2026, expected to

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Fri, 14 Aug 2026 08:00:00 -0400

Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline

LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027

Closed private placement financing, receiving $115 million in upfront gross proceeds, with potential for up to an additional $83 million upon exercise of warrants (including warrants issued to former Orphai stockholders)

Cash and cash equivalents of $116 million as of June 30, 2026, expected to